LOOK TO HEAL™
Introducing Point-of-Care Imaging to Wound Care
MolecuLight Inc. was founded by Dr. Ralph DaCosta and incorporated on June 1, 2012. The company’s first product, the MolecuLight i:X, is a first-of-its kind handheld imaging device based on Dr. DaCosta’s invention.
MolecuLight is based in Toronto, Canada.
MolecuLight’s mission is to become the ubiquitous name in fluorescence-guided imaging technologies to improve health outcomes for patients globally through innovative products and services that optimize the delivery of health care and become standard of care in Wound Care and Breast Cancer.
Using MolecuLight i:X for wound assessment with clinical signs and symptoms allows clinicians to safely and easily identify more wounds containing elevated bacterial burden (104 CFU/g), and measure wounds at the point-of-care. MolecuLight i:X is:
Intended Use & Indication for Use
The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: